Dowsett M, Harris A L, Smith I E, Jeffcoate S L
J Clin Endocrinol Metab. 1984 Jan;58(1):99-104. doi: 10.1210/jcem-58-1-99.
About one third of unselected postmenopausal women with advanced breast cancer respond to treatment with aminoglutethimide and hydrocortisone, but they all eventually relapse, and further progression of disease occurs. In this study, 36 patients who initially responded to this treatment were evaluated to determine whether clinical relapse was associated with escape from endocrine suppression. Plasma estrone levels rose significantly (mean increase, 6.8 pg/ml) during the final 15% of time on treatment before relapse. Mean plasma estradiol, dehydroepiandrosterone sulfate, and androstenedione levels also rose with the approach of the relapse, but the increases were not statistically significant. The increase in estrone may contribute to the progression of disease.
在未经挑选的绝经后晚期乳腺癌女性中，约三分之一对氨鲁米特和氢化可的松治疗有反应，但她们最终都会复发，且疾病会进一步进展。在本研究中，对最初对该治疗有反应的36例患者进行了评估，以确定临床复发是否与内分泌抑制解除有关。在复发前治疗的最后15%时间内，血浆雌酮水平显著升高（平均升高6.8 pg/ml）。随着复发临近，血浆雌二醇、硫酸脱氢表雄酮和雄烯二酮水平也有所升高，但升高无统计学意义。雌酮升高可能促成疾病进展。
